AstraZeneca Shares Fall Most Since 2008 on Brilinta
This article is for subscribers only.
AstraZeneca Plc fell the most in more than two years in London trading after the U.K. drugmaker failed to win U.S. approval for a new blood thinner to rival Plavix, the world’s second-best selling drug.
The stock dropped 212 pence, or 6.7 percent, to 2,941 pence, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.